FDA approves polypill for hypertension

05/15/2009 | MedPage Today (free registration)

The FDA has approved the polypill Exforge HCT for treating hypertension. Novartis Pharmaceuticals' Exforge HCT includes the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan and the diuretic hydrochlorothiazide. FDA said the drug can be substituted for patients already on all three individual drugs or given to patients who don't fully respond to medications in two of three drug classes involved in the therapy.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC